Security Reports > Catalyst Pharmaceuticals

Catalyst Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report

https://catalystpharma.com  ᛫ 
Last updated August 15, 2020

Catalyst Pharmaceuticals Security Rating

${grade.letter}
${cstarScore}
/ 950

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Catalyst Pharmaceuticals is implementing good security practices.

Company Information

Company:
${companyName}
Valuation:
${marketCap}
Employees:
${employees}
Location:
${country}
CEO:
${ceo}

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company based in Coral Gables, Florida. The company is developing therapeutics for rare neurological diseases, including the phosphate salt of amifampridine for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) under the trade name "Firdapse", and CPP-115 (a GABA transaminase) for the treatment of infantile spasms.


Data Breaches and Security News


Security Report for Catalyst Pharmaceuticals

Want a security rating for your organization?

This report shows a preliminary security rating for Catalyst Pharmaceuticals. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.

Get a deeper scan

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Catalyst Pharmaceuticals's security performance with other companies